Bristol Myers Squibb Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla® in Pivotal Phase 3 Psoriasis Study Biotech Investing
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Biotech Investing
Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 Biotech Investing
BioHarvest Sciences Inc. Appoints Highly Acclaimed Advocate, Mr. Roberto Chait, to Company Advisory Board Biotech Investing
AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ in Atopic Dermatitis Biotech Investing
